PTGX · Company research
Protagonist Therapeutics, Inc (PTGX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo! Finance Canada | Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 18, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Stock May Look Fully Priced On Earnings - Simply Wall Street | Protagonist Therapeutics (PTGX) Stock May Look Fully Priced On Earnings Simply Wall Street | View source ↗ | Simply Wall Street | Oct 16, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup - ChartMill | Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup ChartMill | View source ↗ | ChartMill | Oct 16, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know | Protagonist Therapeutics has been upgraded to Zacks Rank #1 (Strong Buy) due to rising earnings estimates. The biopharmaceutical company's consensus estimate has increased 44.1% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improved business fundamentals that could drive near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know | Protagonist Therapeutics has been upgraded to Zacks Rank #1 (Strong Buy) due to rising earnings estimates. The biopharmaceutical company's consensus estimate has increased 44.1% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improved business fundamentals that could drive near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance | Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group - MarketBeat | Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 12, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners - MarketBeat | Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen - MarketBeat | Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. - Stock Titan | After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts - MarketBeat | Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. - Stock Titan | Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - Simply Wall Street | Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run Simply Wall Street | View source ↗ | Simply Wall Street | Sep 4, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance | Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News Yahoo Finance | View source ↗ | Yahoo Finance | Sep 1, 2026 | neutral | 0 | 0.6 |
| PTGX (PTGX) insider files to sell 225,000 shares under Rule 144 - Stock Titan | PTGX (PTGX) insider files to sell 225,000 shares under Rule 144 Stock Titan | View source ↗ | Stock Titan | Aug 10, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Stock Price Surges After Profit Inflection - Simply Wall Street | Protagonist Therapeutics (PTGX) Stock Price Surges After Profit Inflection Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| Two New Hires Get Protagonist Stock Awards Vested Over Four Years - Stock Titan | Two New Hires Get Protagonist Stock Awards Vested Over Four Years Stock Titan | View source ↗ | Stock Titan | Aug 4, 2026 | neutral | 0 | 0.6 |
| Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance | Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review Yahoo Finance | View source ↗ | Yahoo Finance | Jul 9, 2026 | neutral | 0 | 0.6 |
| PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - Yahoo Finance | PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 7, 2026 | neutral | 0 | 0.6 |
| PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView | PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? TradingView | View source ↗ | TradingView | Jul 7, 2026 | neutral | 0 | 0.6 |
| New hires at Protagonist receive stock options at $112.46 - Stock Titan | New hires at Protagonist receive stock options at $112.46 Stock Titan | View source ↗ | Stock Titan | Jun 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.